all prices

price high low   %
Dow Jones 27963 27976 27689 0.99 %
S&P500 3145 3146 3118 0.85 %
Nasdaq 100 8385 8389 8311 0.89 %
Euro Stoxx 50 3691 3694 3657 0.96 %
FTSE 100 7240 7242 7149 1.34 %
CAC40 5872 5877 5818 0.96 %
DAX 13160 13172 13061 0.62 %
Hong Kong HSI 26536 26564 26291 1.18 %
Nikkei 225 23543 23572 23329 0.81 %

Live stock markets prices

Dow Jones 27962 0.99%
S&P500 3145 0.86%
Nasdaq 100 8385 0.89%
FTSE 100 7240 1.34%
CAC40 5872 0.96%
Nikkei 225 23545 0.82%
Euro Stoxx 50 3691 0.96%
DAX 13160 0.62%

Latest news

American medical device specialist joins the board of directors of WATGEN MEDICAL A/S
Nexans : Information on share capital and voting rights - November 2019
Domo, Inc. (DOMO), Infosys Limited (INFY) & Pareteum Corporation (TEUM) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Upcoming Deadlines
DEADLINE ALERT - Ruhnn Holding Limited (RUHN) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: December 6, 2019
SHAREHOLDER ALERT - Sonim Technologies, Inc. (SONM) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: December 6, 2019
DEADLINE ALERT - The Chemours Company (CC) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: December 9, 2019
Alliance Trust PLC - Net Asset Value
Norwegian Finans Holding ASA: Bank Norwegian AS - issuance of senior unsecured bonds
Bank Norwegian AS: Bank Norwegian AS - issuance of senior unsecured bonds
Form 8.3 - [Allergan plc]
Form 8.3 - [ AbbVie Inc.]
Middlefield Canadian Income PCC: Net Asset Value(s)
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.33 per Share
Prophix Software Recognized as November 2019 Gartner Peer Insights Customers’ Choice for Cloud Financial Planning Analysis Solutions
Leading Victim Notification Service Celebrates 25 Years
2nd Watch Earns 2019 Cloud Services Provider of the Year Award
Beter Bed Holding announces sale and lease-back of the distribution centers in Hoogeveen and Nieuw-Vennep
VILNIAUS BALDAI AB investor's calendar for 2020FY
Share Buy-back programme at SP Group A/S
Friday, 6 December 2019, 16:11

American medical device specialist joins the board of directors of WATGEN MEDICAL A/S

Company Announcement No. 20
Vejle, December 6th, 2019

American medical device specialist Jonathan Sorger, Vice President - Research, INTUITIVE SURGICAL (NASDAQ: ISRG), joins the board of directors of WATGEN MEDICAL A/S.


Waturu Holding A/S owns 87.5% of WATGEN MEDICAL A/S. The remaining ownership is split between Belair Medical ApS with 10%, owned by co-founder, doctor and professor, Peter Bjerring and by Huidzaken Holding ApS with 2.5%, owned by Jesper Nørregaard, CEO WATGEN MEDICAL A/S.

WATGEN MEDICAL A/S is developing solutions to ensure better treatment of chronic wound care patients. WATGEN MEDICAL A/S also researches in the development of a new type of treatment for patients with inflammatory skin diseases such as childhood eczema.

About the new board profile:

Jonathan Sorger comes with an MBA from John Hopkins University, Ph.D, Biomedical Engineering, JH School of Medicine as well as B.S., Bioengineering from the University of California. Jonathan Sorger has a broad experience in the field of life-science and within medical equipment technology. Jonathan Sorger is a skilled technical specialist with a focus on commercialization. He is an inventor and co-inventor of more than 20 issued or pending patents. He has also achieved impressive results in identifying and addressing significant unmet clinical needs, with innovative technology solutions. 

“The impact of a diabetic foot ulcer on the life of a patient can be devastating - causing repeated hospitalizations, surgeries for vascular repair, even amputation.  With a lifetime risk of a diabetic patient developing this complication estimated to be up to 15% and the cost to heal an average of $20,000 USD, the opportunity to meaningfully impact patient’s lives and reduce the cost-burden to healthcare systems around the world is significant”- says Jonathan Sorger.

"It is with great pleasure that I welcome Jonathan and I expect Jonathan to be able to contribute actively with knowledge and networks within wound care, which is a large market in the US - as it is globally" - says CEO Jesper Nørregaard.

Jonathan Sorger becomes the first foreign member of the board of directors of WATGEN MEDICAL A/S, where an expectation was previously announced to the market, based on an LOI with a professional investor, about a PRE-IPO capital increase of 10 MDKK to WATGEN MEDICAL A/S. The LOI agreement also includes the investor participating in an upcoming IPO of WATGEN MEDICAL A/S, where a value estimate of +250 MDKK is expected, based on the market as well as external professional investors.

More information:
CEO Toke Reedtz, tel .: +45 5188 1262, e-mail: toke@waturu.com
CFO Michael Nørgaard, tel .: +45 2720 6214, e-mail: mn@waturu.com

Waturu Holding A/S
Sjællandsgade 32
7100 Vejle

Certified Adviser
Västra Hammen Corporate Finance AB
Per Lönn, tel +46 40 200 255
Jungmansgatan 12 211 11 Malmö Sweden
www.vhcorp.se

Nasdaq First North Growth Market Important links:

The website:
www.waturu.com

Financial reports:
www.waturu.com/documents

Continuous updates from the company:
www.waturu.com/news
www.linkedin.com/company/waturu/
www.facebook.com/WaturuDenmark/